Strategic Partnerships ChromaTan recently integrated with Landmark Bio LLC, indicating a channel for co-development opportunities and joint go-to-market activities in viral vector process development and GMP manufacturing.

Funding Momentum Recent NIH phase IIB grant of 2 million dollars signals validation of their BioRMB Process Development System and potential for accelerated scale-up, representing entry points for pilot collaborations and funded trials.

Technology Advantage Their columnless continuous chromatography platform and Kascade BioRMB system target cost reductions, higher purity, and reduced resin consumption, aligning with biopharma clients seeking cheaper, scalable purification solutions.

Leadership Narrative New CEO Rajiv Datar joined in 2023 amid growth signals, suggesting a strategic shift and potential for enterprise-grade partnerships with mid-to-large biopharma/CDMOs seeking innovative purification tech.

MarketPositioning Focus on single-use, continuous chromatography positions ChromaTan to address cost-sensitive markets and rapid deployment needs, offering a competitive hook for clinical and commercial manufacturing customers seeking agile purification platforms.